Meeting
2020 Genitourinary Cancers Symposium
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer.
Authors
Akash Patnaik
Beth Israel Deaconess Medical Center/Dana-Farber Cancer Institute, Boston, MA
Akash Patnaik , Priyanka Duttagupta , Kiranj Chaudagar , Raanan Alter , Hanna Hieromnimon , Russell Zelig Szmulewitz , Gini F. Fleming , Walter Michael Stadler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03572478
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS270)
Abstract #
TPS270
Poster Bd #
P14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.
First Author: Raanan Alter
Poster
2018 ASCO Annual Meeting
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
First Author: Karim Fizazi
Poster
2021 ASCO Annual Meeting
Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).
First Author: Christopher T Su
Poster
2021 ASCO Annual Meeting
Complementary detection of genomic alterations in metastatic castration‑resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.
First Author: Mark Sausen